Nancy Reyes Montes de Oca
Summary
In Mexico, type 2 diabetes is one of
the main causes of blindness,
chronic renal failure and non-
traumatic amputations, and is one
of the 10 most frequent causes of
hospitalization in adults. In
addition, it increases the risk of
suffering a myocardial or cerebral
infarction, and explains 30% of
general mortality.
Based on data from the
aforementioned national surveys;
estimated that, by 2030, the
prevalence of type 2 diabetes
mellitus would reach 12 to 18%, and
by 2050, from 14 to 22%.
Introduction
Methods
Over time, the type of
pharmacological treatment for
people living with diabetes has
changed; exclusive treatment with
oral hypoglycemic agents, the use
of insulin, the use of glycosylated
hemoglobin to monitor the control
of the disease, however, not all
patients do not follow their
treatment to such an extent that
they permanently abandon it due
to the constant consumption of
drugs that interferes with the daily
activities of these patients.
The research and development of
an alternative treatment becomes
potentially interesting and
necessary, or, much more
attractive, of a procedure that
makes it possible to cure the
disease, without patients
presenting complications at the
vascular level in the event that the
control of the blood glucose is
insufficient.
Studies on gene therapy have
begun with the aim of being able to
use it for the treatment of diabetes
mellitus, however, they are only
limited to achieving an
autoimmune response by
preventing the destruction of these
cells. Therefore, I believe that
something more innovative could
be invented that truly eradicates
the disease.
Source: https://www.commonwealthfund.org/
Friday 21st October 2022
THE ULTIMATE CURE FOR
DIABETES
MELLITUS
TYPE 2
Source: https://www.practo.com/
A NEW DRUG REVOLUTION
Conclusion and future prospects
Mechanisms involving autoimmune
destruction of pancreatic beta-cells
and peripheral tissue resistance to
insulin have been suggested to cause
diabetes mellitus.
With molecular bases and gene
therapy, it is possible to develop a
drug with a mechanism of action that
can regenerate pancreatic beta-cells
at a speed that only a single dose is
enough to obtain a favorable
response to treatment.
In such a way that this form of cell
replacement is no longer destroyed
by the patient's own immune system
and does not involve complications,
such as those caused by the use of
immunosuppressants in the case of
pancreas and pancreatic islet
transplants.
Basically, the cells of the
extrapancreatic tissues will be able to
“biologically design” themselves to
express insulin. These include liver
tissue, bone marrow, and circulating
monocytes. Supported by multiple
studies that the liver shares an
embryonic endodermal origin with
the pancreas, it is shown that the cells
can be manipulated to induce the co-
expression of insulin and glucagon.
Source: https://www.tipacilar.com/diabetes-mellitus/
The innovation of this new drug turns
out to be a hopeful and viable tool
towards the cure of type 2 diabetes
mellitus, although it still has to
advance in the research stages and
must continue with an arduous path
of applications in animal models in
order to confirm its efficacy long
term, and to be able to be used in the
clinic with accessibility for all people.
In addition, the advances reflect that,
in the future, apart from achieving a
cure for the disease through
biotechnology, restoring absent
insulin levels, it would also be possible
to allocate similar drugs for the
prevention of this condition, indirectly
managing to counteract the various
secondary complications. that
patients with diabetes mellitus
present.
References
Boada, C. C., & Martinez-Moreno, J. M. (2013).
Pathophysiology of diabetes mellitus type 2:
beyond the duo “insulin resistance-
secretion deficit”. Nutricion hospitalaria,
28(2), 78-87.
DeFronzo, R. A., Ferrannini, E., Groop, L.,
Henry, R. R., Herman, W. H., Holst, J. J., ... &
Weiss, R. (2015). Type 2 diabetes mellitus.
Nature reviews Disease primers, 1(1), 1-22.
Ginter, E., & Simko, V. (2013). Type 2 diabetes
mellitus, pandemic in 21st century.
Diabetes, 42-50.
Denova-Gutiérrez, E., Muñoz-Aguirre, P.,
Shivappa, N., Hébert, J. R., Tolentino-Mayo,
L., Batis, C., & Barquera, S. (2018). Dietary
inflammatory index and type 2 diabetes
mellitus in adults: the diabetes mellitus
survey of Mexico City. Nutrients, 10(4), 385.